- Home
- ESNT vs CANF Comparison
ESNT vs CANF Comparison
Compare ESNT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESNT | CANF |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | Bermuda | Israel |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.7M |
| IPO Year | 2013 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ESNT | CANF |
|---|---|---|
| Price | $57.70 | $3.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $67.86 | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 691.8K | 608.8K |
| Earning Date | 05-08-2026 | 03-27-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ 0.73 | N/A |
| EPS | ★ 6.90 | N/A |
| Revenue | ★ $1,260,935,000.00 | N/A |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | $3.27 | $290,391.28 |
| P/E Ratio | $8.39 | ★ N/A |
| Revenue Growth | ★ 1.45 | N/A |
| 52 Week Low | $51.61 | $0.17 |
| 52 Week High | $67.09 | $10.40 |
Technical Indicators
Market Signals| Indicator | ESNT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 38.10 |
| Support Level | $56.84 | $0.60 |
| Resistance Level | $61.99 | $4.74 |
| Average True Range (ATR) | 1.08 | 0.65 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 20.50 | 1.27 |
Price Performance
Historical ComparisonAbout ESNT Essent Group Ltd.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.